Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza

Model scores of the 29,894 trials active now.

Model score 12% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 6% of the time (876 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-05-14. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: acuteonsethourssubjects withkey
  Phrases that lowered it: evaluate theinfluenzarhinitispharmacokineticsto evaluate
• Sponsor's past termination rate: 13.6% (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Phase: 3 (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 13.6% (lowers risk) · Drug's FDA history
• Minimum age: 0 (lowers risk) · Who can join
• Drug's FAERS reports marked serious: 75.6% (lowers risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Maximum age: 17 (raises risk) · Who can join
• Disease area, respiratory: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 5 (lowers risk) · Sponsor's track record
• Disease area, neurology: No (lowers risk) · Disease area
• Sponsor's past trials: 22 (lowers risk) · Sponsor's track record
• Number of arms: 2 (raises risk) · Design
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza NCT02635724 · started 2015 · scored riskier than 55% of active trials completed
• Peramivir Treatment Response in Adults Hospitalized for Influenza-associated Lower Respiratory Tract Infections NCT02665351 · started 2011 · scored riskier than 71% of active trials completed
• A Study of Intravenous Tamiflu (Oseltamivir) in Children With Influenza NCT01033734 · started 2010 · scored riskier than 9% of active trials completed
• A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection NCT01715909 · started 2014 · scored riskier than 8% of active trials completed
• Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza NCT00610935 · started 2008 · scored riskier than 29% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.